Nearly 30 percent of clinical trial participants withdraw before study completion in certain therapeutic areas, according … Why Pharma Companies Struggle With Trial Participant RetentionRead more
Author: Jayshree Gondane
Jayshree Gondane,
BHMS student and healthcare enthusiast with a genuine interest in medical sciences, patient well-being, and the real-world workings of the healthcare system.
The Role of Marketing in Accelerating Clinical Trial Enrollment
A pivotal oncology trial enrolling 600 patients across 80 U.S. sites can burn through millions of … The Role of Marketing in Accelerating Clinical Trial EnrollmentRead more
Why U.S. Clinical Trial Timelines Keep Getting Longer
The average time required to bring a new medicine from discovery to approval in the United … Why U.S. Clinical Trial Timelines Keep Getting LongerRead more
How Lack of Patient-Centricity Hurts Clinical Trial Outcomes
In 2023, the FDA’s Center for Drug Evaluation and Research approved 55 novel drugs, continuing a … How Lack of Patient-Centricity Hurts Clinical Trial OutcomesRead more
Top Clinical Trial Challenges No One in Pharma Talks About
The U.S. pharmaceutical industry invests heavily in marketing, with estimates from Statista showing that spending on … Top Clinical Trial Challenges No One in Pharma Talks AboutRead more
The Biggest Reasons Clinical Trials Fail to Scale
Clinical trials are the cornerstone of pharmaceutical innovation, providing the evidence necessary to bring safe and … The Biggest Reasons Clinical Trials Fail to ScaleRead more
Why Many Biotech Startups Never Make It Past Early Trials
Over 90% of biotech startups never advance beyond early clinical trials, a statistic that underscores the … Why Many Biotech Startups Never Make It Past Early TrialsRead more
How Poor Trial Design Increases Drug Development Costs
In pharmaceutical development, clinical trials serve as the backbone of bringing a new therapy from concept … How Poor Trial Design Increases Drug Development CostsRead more
Why Phase II Clinical Trials Are the Graveyard of Drug Development
Nearly 60 percent of drug candidates that enter Phase II clinical trials never advance to Phase … Why Phase II Clinical Trials Are the Graveyard of Drug DevelopmentRead more
What Happens When Pharma Ignores Real-World Evidence
In 2023, nearly half of drugs approved by the U.S. Food and Drug Administration faced post-launch … What Happens When Pharma Ignores Real-World EvidenceRead more